CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 05/12/21

Cyclacel Pharmaceuticals (CYCC): Q1 GAAP EPS of -$1.48 misses by $0.99.As of March 31, 2021, cash and cash equivalents totaled $47.8 million, compared to $33.4 million as of December 31, 2020.Press Release For further details see: Cyclacel Pharmaceuticals EPS misses by $0.99

- Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors - - Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition - - Following Recent Financing, Cash Runway Extended to Early 2023 - - Conf...

BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter financial results an...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and welcome to the final stretch of the week for investors before a couple of days away from the stock market! Let’s start off the end of the week off right with another great day of trading as we look o...

Today, we take our first in-depth look at Cyclacel Pharmaceuticals, a stock that has destroyed so much shareholder value over the years. However, the shares have rallied over the past few months.  Can that continue?  We attempt to find out. A full investment analysis fol...

The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this event. For further details see: Cyclacel Pharmaceuticals (CYCC) Presents At 33rd Annual Roth Virtual Conference - Slideshow

BERKELEY HEIGHTS, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously ...

BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at th...

Cyclacel Pharmaceuticals (CYCC) announces the pricing of an underwritten public offering of 1.8M shares at $7/share with expected gross proceeds of $12.65M.Intends to use the net proceeds to support the company’s growth strategy and for working capital and general corporate purposes, i...

BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten...